<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27845">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744222</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-054-2</org_study_id>
    <nct_id>NCT02744222</nct_id>
  </id_info>
  <brief_title>Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis</brief_title>
  <official_title>International Multi-center Double-blind Comparative Randomized Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 (JSC &quot;BIOCAD&quot;, Russia) 120 mcg or 180 mcg Intramuscularly, Biweekly and Avonex® (Biogen Idec Limited, Great Britain) 30 mcg, Weekly, for Treatment of Patients With Remitting-relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      International multi-center double-blind comparative randomized clinical trial to evaluate
      efficacy, safety and tolerance of BCD-054 (JSC &quot;BIOCAD&quot;, Russia) 120 mcg or 180 mcg
      intramuscularly, biweekly and Avonex® (Biogen Idec Limited, Great Britain) 30 mcg, weekly,
      for treatment of patients with remitting multiple sclerosis
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average annual rate of exacerbations</measure>
    <time_frame>Week 52, Week 104</time_frame>
    <description>Average annual rate of exacerbations is calculated based on the number of confirmed relapses per year during BCD-054 / Avonex® therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients without relapse</measure>
    <time_frame>Week 52, Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time before first relapse and risk of relapse</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CUA</measure>
    <time_frame>Week 52, Week 104</time_frame>
    <description>CUA (combined unique active) - the cumulative number of new accumulating contrast lesions on MRI in T1 mode, and new lesions in T2-weighted or any increase in foci in T2 mode</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AE/SAE</measure>
    <time_frame>104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who develop binding and neutralizing antibodies to study drug</measure>
    <time_frame>104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-168 hours)</measure>
    <time_frame>0 to 168 hours after 1 study drug injection</time_frame>
    <description>AUC (0-168 hours) - area under curve &quot;concentration - time&quot; from 0 to 168 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-336 hours)</measure>
    <time_frame>from 0 to 336 hours after 1 study drug injection</time_frame>
    <description>AUC (0-336 hours) - area under curve &quot;concentration - time&quot; from 0 to 336 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC (0-168 hours)</measure>
    <time_frame>from 0 to 168 hours after 1 study drug injection</time_frame>
    <description>AUEC (0-168 hours) - area under effect curve &quot;concentration of MxA-protein/neopterin - time&quot; from 0 to 168 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC (0-336 hours)</measure>
    <time_frame>from 0 to 336 hours after 1 study drug injection</time_frame>
    <description>AUEC (0-336 hours) - area under effect curve &quot;concentration of MxA-protein/neopterin - time&quot; from 0 to 336 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCss (0-168 hours, 0-336 hours)</measure>
    <time_frame>from 0 to 168 hours and from 0 to 336 hours after injection 29</time_frame>
    <description>AUCss (0-168 hours, 0-336 hours) - area under curve &quot;concentration - time&quot; from 0 to 168 hours and from 0 to 336 hours(after injection №29, in steady state conditions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUECss (0-168 hours, 0-336 hours)</measure>
    <time_frame>from 0 to 168 hours and from 0 to 336 hours after injection 29</time_frame>
    <description>AUECss (0-168 hours, 0-336 hours) - area under effect curve &quot;concentration of MxA-protein/neopterin - time&quot; from 0 to 168 hours and from 0 to 336 hours (after injection №29, in steady state conditions)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>BCD-054, 120 mcg, biweekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive study drug injections intramuscularly every 2 weeks and placebo injections every week up to Week 52, then patients will receive open label therapy in the same regimen up to Week 104.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-054, 180 mcg, biweekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive study drug injections intramuscularly every 2 weeks and placebo injections every week up to Week 52, then patients will receive open label therapy in the same regimen up to Week 104.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Avonex®, 30 mcg, weekly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive study drug injections intramuscularly every week up to Week 52, then patients will receive open label therapy in the same regimen up to Week 104.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCD-054</intervention_name>
    <arm_group_label>BCD-054, 120 mcg, biweekly</arm_group_label>
    <arm_group_label>BCD-054, 180 mcg, biweekly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Avonex®</intervention_name>
    <arm_group_label>Avonex®, 30 mcg, weekly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Written informed consent Diagnosis of remitting multiple sclerosis according to McDonald
        criteria (2010) Minimum 1 relapse during last 12 months prior to screening Minimum 1 focus
        in brain that accumulates gadolinium (T1-weighted images) or 1 new focus (T2-weighted
        images) Patient has stable neurological state during last 30 days prior to screening EDSS
        score from 0 to 4,5

        Exclusion Criteria:

        Secondary progressive and primary progressive forms of MS Other diseases that could
        influence course of the disease or symptoms assessment Relapse on screening or before 1
        study drug injection

        History of use:

          -  interferon beta-1a, interferon beta 1b,

          -  glatiramer acetate during last 30 days prior to randomization,

          -  monoclonal antibodies, cytotoxic or immunosuppressive drugs last 6 months prior to
             randomization, Use of corticosteroids intravenously or orally last 30 days prior to
             randomization.

        Intolerance or allergy to interferon beta or other excipients of BCD-054 or Avonex® or
        pegylated proteins

        Full list of inclusion and exclusion criteria can be found in Protocol of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Ivanov, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>JCS BIOCAD</affiliation>
  </overall_official>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 15, 2016</lastchanged_date>
  <firstreceived_date>April 3, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
